SEARCH:   Advanced

Blood, 1 January 2004, Vol. 103, No. 1, pp. 58-66. Prepublished online as a Blood First Edition Paper on August 7, 2003; DOI 10.1182/blood-2003-05-1611. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-05-1611v1 103/1/58    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Maignan, C. l. Articles by Andrieu, J.-M. Search for Related Content PubMed PubMed Citation Articles by Maignan, C. l. Articles by Andrieu, J.-M. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial Christine le Maignan, Bernard Desablens, Vincent Delwail, Mahmoud Dib, Christian Berthou, Magda Vigier, Christiane Ghandour, Saïd Atmani, Philippe Casassus, Hervé Maisonneuve, Annick Le Mevel, Catherine Traullé, Marc Bernard, Josette Brière, Pierre Colonna, and Jean-Marie Andrieu From the Cancérologie Médicale, Hôpital Européen Georges Pompidou, Paris, France; Hématologie, Hôpital Sud, Amiens, France; Hématologie, Hôpital Jean Bernard, Poitiers, France; Maladies du Sang, CHU d'Angers; Hématologie, Hôpital Morvan, Brest, France; Hématologie, Hôtel Dieu, Nantes, France; 83 avenue Aristide Briand, Rennes, France; Hématologie, Hôpital Beaujon, Clichy, France; Hématologie, Hôpital Avicenne, Bobigny, France; Médecine A Centre Hospitalier Départemental, La Roche sur Yon, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Hématologie, Hôpital Pontchaillou, Rennes, France; and Anatomie Pathologique, Hôpital Saint-Louis, Paris, France. From 1990 to 1996, a total of 386 adult patients with early/intermediate Hodgkin disease (HD) were randomly assigned to receive 3 cycles of adriamycin, bleomycin, vinblastine, dacarbazine (an alkylating agent), and methylprednisolone (ABVDm, arm A) or epirubicin, bleomycin, vinblastine, methotrexate, and methylprednisolone (EBVMm, arm E), a combination without alkylating agent. Responding patients received extended field radiation therapy (RT). Postchemotherapy complete remission and 10-year freedom from progression rates were higher in arm A (79.5% and 91.4%) than in arm E (70.4%, P = .04, and 80%, P < .002). HD mortality (HDM), treatment-related mortality (TRM), and overall survival (OS) were similar in both arms (A, 2.1%, 7.5%, and 90.4%; B, 3.9%, 5.5%, and 90.3%). However TRM and OS rates were lower in patients aged 40 years or older (P < .005), reflecting the increasing incidence of background fatal events with increasing age. Finally, event-free survival (EFS) was higher in arm A (84.6%) than in arm E (74.9%, P < .02). In patients aged younger than 40 years in arm A (74%), 10-year EFS and OS rates were 88.9% and 95.4% with HDM and TRM rates as low as 0.7% and 3%. Three courses of ABVDm plus RT are the best available option for treating early or intermediate HD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF] P. Feugier, E. Labouyrie, M. Djeridane, A. Jenabian, V. Dubruille, C. Berthou, C. Ghandour, B. Desablens, Y. Chait, P. Casassus, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation Blood, November 1, 2004; 104(9): 2675 - 2681. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020